Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biological Specimen Banks | 4 | 2022 | 57 | 1.040 |
Why?
|
| Tetralogy of Fallot | 2 | 2025 | 171 | 0.830 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2025 | 173 | 0.830 |
Why?
|
| Stroke Volume | 1 | 2025 | 515 | 0.750 |
Why?
|
| Ventricular Function, Left | 1 | 2025 | 521 | 0.700 |
Why?
|
| Retinoblastoma | 3 | 2012 | 79 | 0.690 |
Why?
|
| Echocardiography | 1 | 2025 | 1114 | 0.600 |
Why?
|
| Biomedical Research | 3 | 2020 | 531 | 0.570 |
Why?
|
| Retinal Neoplasms | 2 | 2012 | 68 | 0.430 |
Why?
|
| Oncolytic Viruses | 3 | 2013 | 75 | 0.430 |
Why?
|
| Heart Septal Defects | 2 | 2025 | 36 | 0.400 |
Why?
|
| Picornaviridae | 2 | 2013 | 18 | 0.380 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2012 | 84 | 0.370 |
Why?
|
| Antigens, CD | 1 | 2012 | 415 | 0.320 |
Why?
|
| Glycoproteins | 1 | 2012 | 333 | 0.320 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 606 | 0.300 |
Why?
|
| Retina | 1 | 2012 | 445 | 0.290 |
Why?
|
| Peptides | 1 | 2012 | 829 | 0.290 |
Why?
|
| Mitral Valve Stenosis | 1 | 2025 | 34 | 0.230 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2007 | 191 | 0.230 |
Why?
|
| Genetic Therapy | 1 | 2007 | 683 | 0.200 |
Why?
|
| Public Opinion | 1 | 2022 | 58 | 0.190 |
Why?
|
| Reoperation | 1 | 2025 | 818 | 0.180 |
Why?
|
| Genome-Wide Association Study | 2 | 2020 | 1728 | 0.170 |
Why?
|
| Receptor, Notch4 | 1 | 2020 | 4 | 0.170 |
Why?
|
| Oncolytic Virotherapy | 2 | 2013 | 89 | 0.170 |
Why?
|
| Bacillus | 1 | 2000 | 36 | 0.170 |
Why?
|
| Repressor Proteins | 2 | 2016 | 761 | 0.160 |
Why?
|
| Research Personnel | 1 | 2020 | 123 | 0.150 |
Why?
|
| Cytoskeletal Proteins | 1 | 2020 | 273 | 0.150 |
Why?
|
| Neoplasm Transplantation | 2 | 2011 | 361 | 0.150 |
Why?
|
| Progesterone | 1 | 2000 | 427 | 0.140 |
Why?
|
| Down Syndrome | 1 | 2020 | 200 | 0.140 |
Why?
|
| Antigens, Neoplasm | 1 | 2020 | 398 | 0.140 |
Why?
|
| Hypoplastic Left Heart Syndrome | 2 | 2022 | 269 | 0.140 |
Why?
|
| Heart Defects, Congenital | 2 | 2022 | 1853 | 0.140 |
Why?
|
| Brain Neoplasms | 3 | 2013 | 1224 | 0.130 |
Why?
|
| Child | 6 | 2025 | 25101 | 0.130 |
Why?
|
| Proteomics | 1 | 2020 | 562 | 0.130 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 677 | 0.120 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2025 | 1162 | 0.120 |
Why?
|
| RNA Splicing Factors | 1 | 2016 | 52 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2016 | 32 | 0.120 |
Why?
|
| Quality Control | 1 | 2016 | 112 | 0.120 |
Why?
|
| Codon, Nonsense | 1 | 2016 | 139 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2016 | 144 | 0.120 |
Why?
|
| Infant | 3 | 2025 | 12771 | 0.110 |
Why?
|
| Myocytes, Cardiac | 2 | 2022 | 609 | 0.110 |
Why?
|
| Alternative Splicing | 1 | 2016 | 296 | 0.110 |
Why?
|
| Humans | 20 | 2025 | 126754 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 2 | 2012 | 985 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2025 | 3066 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2016 | 2537 | 0.100 |
Why?
|
| Genomics | 1 | 2020 | 1546 | 0.100 |
Why?
|
| Phenotype | 1 | 2022 | 4304 | 0.100 |
Why?
|
| PAX6 Transcription Factor | 1 | 2012 | 37 | 0.090 |
Why?
|
| AC133 Antigen | 1 | 2012 | 35 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2025 | 14347 | 0.090 |
Why?
|
| Paired Box Transcription Factors | 1 | 2012 | 75 | 0.090 |
Why?
|
| Disease Models, Animal | 3 | 2013 | 4429 | 0.090 |
Why?
|
| Immunophenotyping | 1 | 2012 | 330 | 0.090 |
Why?
|
| Eye Proteins | 1 | 2012 | 229 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2012 | 754 | 0.080 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 140 | 0.080 |
Why?
|
| Stem Cells | 1 | 2014 | 683 | 0.080 |
Why?
|
| Mice | 6 | 2013 | 17596 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 538 | 0.070 |
Why?
|
| Glioma | 1 | 2013 | 479 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 331 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 726 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2007 | 85 | 0.070 |
Why?
|
| Medulloblastoma | 1 | 2010 | 378 | 0.060 |
Why?
|
| Female | 8 | 2025 | 68330 | 0.060 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 2310 | 0.060 |
Why?
|
| Hyaluronan Receptors | 1 | 2006 | 64 | 0.060 |
Why?
|
| Cystadenoma, Serous | 1 | 2005 | 6 | 0.060 |
Why?
|
| Transduction, Genetic | 1 | 2006 | 283 | 0.060 |
Why?
|
| Hyaluronic Acid | 1 | 2006 | 101 | 0.060 |
Why?
|
| Azetidines | 1 | 2006 | 64 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 634 | 0.060 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2005 | 56 | 0.060 |
Why?
|
| Male | 4 | 2025 | 62543 | 0.060 |
Why?
|
| Animals | 6 | 2013 | 33051 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 686 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3262 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 333 | 0.060 |
Why?
|
| Phyllodes Tumor | 1 | 2004 | 9 | 0.060 |
Why?
|
| Vaginal Neoplasms | 1 | 2004 | 17 | 0.050 |
Why?
|
| Myxoma | 1 | 2004 | 29 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2006 | 573 | 0.050 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2004 | 61 | 0.050 |
Why?
|
| Leiomyosarcoma | 1 | 2004 | 25 | 0.050 |
Why?
|
| Trimethylsilyl Compounds | 1 | 2003 | 2 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2025 | 12546 | 0.050 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2003 | 39 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2003 | 65 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2005 | 354 | 0.050 |
Why?
|
| Peritoneal Neoplasms | 1 | 2004 | 53 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2004 | 103 | 0.050 |
Why?
|
| Image Cytometry | 1 | 2022 | 11 | 0.050 |
Why?
|
| Bone Morphogenetic Protein Receptors | 1 | 2022 | 11 | 0.050 |
Why?
|
| Steroids | 1 | 2003 | 157 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2013 | 240 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2005 | 443 | 0.040 |
Why?
|
| Chromatography, Thin Layer | 1 | 2000 | 42 | 0.040 |
Why?
|
| Androstenedione | 1 | 2000 | 15 | 0.040 |
Why?
|
| Biotransformation | 1 | 2000 | 53 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2013 | 568 | 0.040 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2022 | 154 | 0.040 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2022 | 207 | 0.040 |
Why?
|
| Monocytes | 1 | 2022 | 330 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2000 | 306 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 360 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 315 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 215 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 313 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2020 | 4954 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2013 | 946 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 319 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 729 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 973 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 142 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2022 | 819 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2004 | 1234 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2022 | 665 | 0.030 |
Why?
|
| Glucose | 1 | 2000 | 839 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2109 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2025 | 3586 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8347 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 775 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 396 | 0.030 |
Why?
|
| Time Factors | 1 | 2025 | 6134 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2014 | 230 | 0.030 |
Why?
|
| Cell Communication | 1 | 2014 | 189 | 0.030 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2013 | 23 | 0.030 |
Why?
|
| Amniotic Fluid | 1 | 2014 | 147 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 1054 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 748 | 0.020 |
Why?
|
| Troponin T | 1 | 2014 | 247 | 0.020 |
Why?
|
| Adult | 4 | 2025 | 30410 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 2582 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2016 | 761 | 0.020 |
Why?
|
| Young Adult | 1 | 2025 | 9665 | 0.020 |
Why?
|
| Risk Factors | 1 | 2025 | 10555 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 251 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 2065 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 235 | 0.020 |
Why?
|
| Adolescent | 2 | 2025 | 20002 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2022 | 4472 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 2595 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2013 | 1495 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 1014 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1222 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1842 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2025 | 17005 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2746 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 2101 | 0.010 |
Why?
|
| Ezetimibe | 1 | 2006 | 94 | 0.010 |
Why?
|
| Pulsatile Flow | 1 | 2005 | 120 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2005 | 184 | 0.010 |
Why?
|
| Mastectomy, Simple | 1 | 2004 | 1 | 0.010 |
Why?
|
| United States | 1 | 2020 | 11310 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 557 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 1811 | 0.010 |
Why?
|
| Omentum | 1 | 2004 | 41 | 0.010 |
Why?
|
| Hydroxylation | 1 | 2003 | 48 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 1877 | 0.010 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2003 | 30 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 3498 | 0.010 |
Why?
|
| Calibration | 1 | 2003 | 92 | 0.010 |
Why?
|
| Catalysis | 1 | 2003 | 133 | 0.010 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2004 | 67 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2006 | 890 | 0.010 |
Why?
|
| Postpartum Period | 1 | 2004 | 226 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 2560 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2006 | 756 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2004 | 619 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 1293 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2004 | 933 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2883 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 4504 | 0.010 |
Why?
|
| Middle Aged | 2 | 2005 | 27697 | 0.010 |
Why?
|
| Mutation | 1 | 2006 | 5941 | 0.010 |
Why?
|
| Pregnancy | 1 | 2004 | 7373 | 0.010 |
Why?
|